

Product Data Sheet

Product Name: TT-OAD2

Cat. No.: GC70629

Chemical Properties

Cas. No. 2382719-60-8

Formula $C_{50}H_{49}Cl_4N_3O_6$ M.Wt 929.75


Solubility DMSO : 110 mg/mL (118.31 mM);
Need ultrasonic; Hygroscopic DMSO
has a significant impact on the
solubility of product, please use
newly opened DMSO)

Storage 4°C, sealed storage, away from
moisture and light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the
ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or
blue ice upon request.

Structure



Background

TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC₅₀ of 5 nM. TT-OAD2 has the potential for diabetes treatment.

TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

arrestin responses in a concentration-dependent manner in HEK293A cells^[1].

TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice^[1].

References:

[1]. Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.

[2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA